Budman D - Search Results

1

Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma.

Scher HI, Yagoda A, Ahmed T, Budman D, Sordillo P, Watson RC. Scher HI, et al. Among authors: budman d. Cancer Chemother Pharmacol. 1985;14(1):79-80. doi: 10.1007/BF00552731. Cancer Chemother Pharmacol. 1985. PMID: 3855289

2

Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.

Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, et al. Daghestani AN, et al. Among authors: budman d. Cancer Res. 1985 Mar;45(3):1408-12. Cancer Res. 1985. PMID: 3855696

3

A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.

Puccio CA, Mittelman A, Lichtman SM, Silver RT, Budman DR, Ahmed T, Feldman EJ, Coleman M, Arnold PM, Arlin ZA, et al. Puccio CA, et al. Among authors: budman dr. J Clin Oncol. 1991 Sep;9(9):1562-9. doi: 10.1200/JCO.1991.9.9.1562. J Clin Oncol. 1991. PMID: 1714949 Clinical Trial.

4

Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule.

Lichtman SM, Mittelman A, Budman DR, Puccio CA, Chun HG, Allen SL, Ahmed T, Arlin ZA. Lichtman SM, et al. Among authors: budman dr. Leuk Lymphoma. 1991;6(1):61-3. doi: 10.3109/10428199109064880. Leuk Lymphoma. 1991. PMID: 27457577

5

Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.

Stanton GF, Raymond V, Wittes RE, Schulman P, Budman D, Baratz R, Williams L, Petroni GR, Geller NL, Hancock C, et al. Stanton GF, et al. Among authors: budman d. Cancer Res. 1985 Apr;45(4):1862-8. Cancer Res. 1985. PMID: 3978646

6

Tamoxifen in unresectable hypernephroma. A phase II trial and review of the literature.

Weiselberg L, Budman D, Vinciguerra V, Schulman P, Degnan TJ. Weiselberg L, et al. Among authors: budman d. Cancer Clin Trials. 1981;4(2):195-8. Cancer Clin Trials. 1981. PMID: 7249256

7

Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis.

Budman DR, Johnson R, Barile B, Bowsher RR, Vinciguerra V, Allen SL, Kolitz J, Ernest CS 2nd, Kreis W, Zervos P, Walling J. Budman DR, et al. Cancer Chemother Pharmacol. 2001 Jun;47(6):525-31. doi: 10.1007/s002800000272. Cancer Chemother Pharmacol. 2001. PMID: 11459206 Clinical Trial.

8

Pharmacokinetic evaluation of zeniplatin in humans.

DeMarco LC, Budman DR, Lathia C, Amorusi P, Birkhofer M, Lichtman S, Weiselberg L, Vinciguerra V, Lovecchio J, Gal D, et al. DeMarco LC, et al. Among authors: budman dr. Cancer Chemother Pharmacol. 1995;36(1):35-40. doi: 10.1007/BF00685729. Cancer Chemother Pharmacol. 1995. PMID: 7720173 Clinical Trial.

9

Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer.

Aisner J, Whitacre MY, Budman DR, Propert K, Strauss G, Van Echo DA, Perry M. Aisner J, et al. Among authors: budman dr. Cancer Chemother Pharmacol. 1992;29(6):435-8. doi: 10.1007/BF00684843. Cancer Chemother Pharmacol. 1992. PMID: 1314712 Clinical Trial.

10

Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy.

Markman M, DeMarco LC, Birkhofer M, Budman D, Hakes T, Reichman B, Rubin S, Jones W, Barakat R, Curtin J, et al. Markman M, et al. Among authors: budman d. J Cancer Res Clin Oncol. 1993;119(4):234-6. doi: 10.1007/BF01624436. J Cancer Res Clin Oncol. 1993. PMID: 8423199 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

211 results

Search Page

Filters